Biomarkers Market

Table of Content

SECTION I: REPORT OVERVIEW

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Introduction

2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Healthcare Providers

2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach

3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis

3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation

3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Biomarkers
6.2.1. Type of Biomarkers
6.2.2. Advantages and Clinical Utility of Biomarkers
6.2.3. Challenges Associated with Biomarkers

6.3. Future Perspective

7. REGULATORY SCENARIO

SECTION III: MARKET OVERVIEW

8. COMPREHENSIVE DATABASE OF LEADING PLAYERS

9. COMPETITIVE LANDSCAPE
9.1. Chapter Overview
9.2. Biomarkers: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters

9.2.4. Biomarkers: Overall Market Landscape
9.2.4.1. Analysis by Offering Type
9.2.4.2. Analysis by Biomarker Type
9.2.4.3. Analysis by Efficacy Biomarker
9.2.4.4. Analysis by Application Area
9.2.4.5. Analysis by Therapeutic Area
9.2.4.6. Analysis by End User

10. PORTER'S FIVE FORCES ANALYSIS

11. COMPETITIVE COMPETITIVENESS ANALYSIS

12. STARTUP ECOSYSTEM IN THE BIOMARKERS MARKET
12.1. Biomarkers: Market Landscape of Startups
12.1.1. Analysis by Year of Establishment
12.1.2. Analysis by Company Size
12.1.3. Analysis by Company Size and Year of Establishment
12.1.4. Analysis by Location of Headquarters
12.1.5. Analysis by Company Size and Location of Headquarters
12.1.6. Analysis by Ownership Structure

12.2. Key Findings

SECTION IV: COMPANY PROFILES

13. COMPANY PROFILES
13.1. Chapter Overview
13.2. Abbott
13.2.1. Company Overview
13.2.2. Company Mission
13.2.3. Company Footprint
13.2.4. Management Team
13.2.5. Contact Details
13.2.6. Financial Performance
13.2.7. Operating Business Segments
13.2.8. Service / Product Portfolio (project specific)
13.2.9. MOAT Analysis
13.2.10. Recent Developments and Future Outlook

* similar detail is presented for other below mentioned companies based on information in the public domain

13.3. Agilent Technologies
13.4. Bio Rad Laboratories
13.5. Bruker
13.6. Charles River Laboratories
13.7. Centogene
13.8. Enzo Biochem
13.9. Epigenomics
13.10. Eurofins Scientific
13.11. EKF Diagnostics Holdings
13.12. Hoffman La Roche
13.13. General Electric
13.14. LifeSign
13.15. Merck
13.16. MESO SCALE DIAGNOSTICS
13.17. Nexus
13.18. PerkinElmer
13.19. QIAGEN
13.20. Sino Biological
13.21. Thermo Fischer Scientific

SECTION V: MARKET TRENDS

14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology

14.3. Biomarkers: Patent Analysis
14.3.1. Analysis by Patent Publication Year
14.3.2. Analysis by Type of Patent and Patent Publication Year
14.3.3. Analysis by Patent Application Year
14.3.4. Analysis by Patent Jurisdiction
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.3.8. Leading Individual Assignees: Analysis by Number of Patents

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models

15.3. Biomarkers: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Type of Partner
15.3.5. Analysis by Location of Headquarters of Partner
15.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
15.3.7. Most Active Players: Analysis by Number of Partnerships

15.3.8. Regional Analysis
15.3.8.1. Intercontinental and Intracontinental Deals
15.3.8.2. Local and International Deals

16. GRANT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology

16.3. Biomarkers: Grant Analysis
16.3.1. Analysis by Year of Grant Award
16.3.2. Analysis by Amount Awarded
16.3.3. Analysis by Support Period
16.3.4. Analysis by Support Period and Funding Institute Center
16.3.5. Analysis by Type of Grant Application
16.3.6. Analysis by Purpose of Grant Award
16.3.7. Analysis By Activity Code
16.3.8. Analysis by NIH Spending Category
16.3.9. Analysis by Study Section Involved
16.3.10. Popular NIH Departments: Analysis by Number of Grants
16.3.11. Analysis by Type of Recipient Organization
16.3.12. Prominent Program Officers: Analysis by Number of Grants
16.3.13. Popular Recipient Organizations: Analysis by Number of Grants
16.3.14. Popular Recipient Organizations: Analysis by Grant Amount
16.3.15. Analysis by Region of Recipient Organizations

17. FUNDING AND INVESTMENTS ANALYSIS
17.1. Funding Models
17.2. Biomarkers: Funding and Investments
17.2.1. Analysis by Year of Funding
17.2.2. Analysis of Funding Instances by Type of Funding
17.2.3. Analysis of Funding Instances by Year and Type of Funding
17.2.4. Analysis of Amount Invested by Type of Funding
17.2.5. Analysis of Funding Instances by Country
17.2.6. Most Active Players: Analysis by Amount Raised

17.3. Summary and Key Takeaways

18. CLINICAL TRIAL ANALYSIS
18.1. Analysis Methodology and Key Parameters
18.2. Biomarkers: Clinical Trial Analysis
18.2.1. Analysis by Trial Status
18.2.2. Analysis by Trial Registration Year
18.2.3. Analysis by Type of Sponsor / Collaborator
18.2.4. Analysis by Type of Study Design
18.2.5. Analysis by Registration Year and Type of Study
18.2.6. Analysis by Patient Enrollment
18.2.7. Year-wise Trend of Completed and Recruiting Trials
18.2.8. Analysis by Age Category
18.2.9. Word Cloud of Study Titles
18.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
18.2.11. Most Active Non- Industry Players: Analysis by Number of Registered Trials
18.2.12. Analysis by Trial Location
18.2.13. Analysis by Trial Status and Geography

SECTION VI: MARKET OPPORTUNITY ANALYSIS

19. GLOBAL BIOMARKERS MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Trends Disruption Impacting Market
19.4. Demand Side Trends
19.5. Supply Side Trends
19.6. Global Biomarkers Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.7. Multivariate Scenario Analysis
19.7.1. Conservative Scenario
19.7.2. Optimistic Scenario

19.8. Investment Feasibility Index
19.9. Key Market Segmentations

20. MARKET OPPORTUNITIES BASED ON TYPE OF OFFERING
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. Biomarkers Market for Consumables: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. Biomarkers Market for Services: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.8. Biomarkers Market for Software: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.9. Data Triangulation and Validation
20.9.1. Secondary Sources
20.9.2. Primary Sources
20.9.3. Statistical Modeling

21. MARKET OPPORTUNITIES BASED ON TYPE OF BIOMARKER
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. Biomarkers Market for Safety Biomarkers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. Biomarkers Market for Efficacy Biomarkers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.8. Biomarkers Market for Validation Biomarkers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.9. Data Triangulation and Validation
21.9.1. Secondary Sources
21.9.2. Primary Sources
21.9.3. Statistical Modeling

22. MARKET OPPORTUNITIES BASED ON TYPE OF EFFICACY BIOMARKER
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix
22.6. Biomarkers Market for Predictive Biomarkers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.7. Biomarkers Market for Surrogate Biomarkers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.8. Biomarkers Market for Pharmacodynamic Biomarkers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.9. Biomarkers Market for Prognostic Biomarkers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.10. Data Triangulation and Validation
22.10.1. Secondary Sources
22.10.2. Primary Sources
22.10.3. Statistical Modeling

23. MARKET OPPORTUNITIES BASED ON APPLICATION AREA
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix
23.6. Biomarkers Market for Diagnostics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.7. Biomarkers Market for Drug Discovery and Development: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.8. Biomarkers Market for Personalized Medicine: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.9. Biomarkers Market for Disease Risk Assessment: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.10. Biomarkers Market for Forensic Application: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.11. Biomarkers Market for Other Application Areas: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.12. Data Triangulation and Validation
23.12.1. Secondary Sources
23.12.2. Primary Sources
23.12.3. Statistical Modeling

24. MARKET OPPORTUNITIES BASED ON THERAPEUTIC AREA
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Revenue Shift Analysis
24.4. Market Movement Analysis
24.5. Penetration-Growth (P-G) Matrix
24.6. Biomarkers Market for Oncological Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.7. Biomarkers Market for Cardiovascular Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.8. Biomarkers Market for Neurological Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.9. Biomarkers Market for Immunological Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.10. Biomarkers Market for Other Therapeutic Areas: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.11. Data Triangulation and Validation
24.11.1. Secondary Sources
24.11.2. Primary Sources
24.11.3. Statistical Modeling

25. MARKET OPPORTUNITIES BASED ON END USER
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Revenue Shift Analysis
25.4. Market Movement Analysis
25.5. Penetration-Growth (P-G) Matrix
25.6. Biomarkers Market for Hospitals and Laboratories: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.7. Biomarkers Market for Diagnostic Centers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.8. Biomarkers Market for Research Organizations: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.9. Biomarkers Market for Other End Users: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.10. Data Triangulation and Validation
25.10.1. Secondary Sources
25.10.2. Primary Sources
25.10.3. Statistical Modeling

26. MARKET OPPORTUNITIES FOR BIOMARKERS IN NORTH AMERICA
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Revenue Shift Analysis
26.4. Market Movement Analysis
26.5. Penetration-Growth (P-G) Matrix

26.6. Biomarkers Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.1. Biomarkers Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.2. Biomarkers Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.3. Biomarkers Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.7. Data Triangulation and Validation

27. MARKET OPPORTUNITIES FOR BIOMARKERS IN EUROPE
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Revenue Shift Analysis
27.4. Market Movement Analysis
27.5. Penetration-Growth (P-G) Matrix

27.6. Biomarkers Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.1. Biomarkers Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.2. Biomarkers Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.3. Biomarkers Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.4. Biomarkers Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.5. Biomarkers Market in The UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.6. Biomarkers Market in Rest of the Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.7. Data Triangulation and Validation

28. MARKET OPPORTUNITIES FOR BIOMARKERS IN ASIA-PACIFIC
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Revenue Shift Analysis
28.4. Market Movement Analysis
28.5. Penetration-Growth (P-G) Matrix

28.6. Biomarkers Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.1. Biomarkers Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.2. Biomarkers Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.3. Biomarkers Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.4. Biomarkers Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.5. Biomarkers Market in Australia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.6. Biomarkers Market in Russia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.7. Biomarkers Market in Thailand: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.8. Biomarkers Market in Malaysia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.9. Biomarkers Market in Indonesia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.6.10. Biomarkers Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

28.7. Data Triangulation and Validation

29. MARKET OPPORTUNITIES FOR BIOMARKERS IN MIDDLE EAST AND NORTH AFRICA (MENA)
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Revenue Shift Analysis
29.4. Market Movement Analysis
29.5. Penetration-Growth (P-G) Matrix

29.6. Biomarkers Market in Middle East and North Africa (MENA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
29.6.1. Biomarkers Market in Iran: Historical Trends (Since 2020) and Forecasted Estimates (Till 205)
29.6.2. Biomarkers Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
29.6.3. Biomarkers Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

29.7. Data Triangulation and Validation

30. MARKET OPPORTUNITIES FOR BIOMARKERS IN LATIN AMERICA
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Revenue Shift Analysis
30.4. Market Movement Analysis
30.5. Penetration-Growth (P-G) Matrix

30.6. Biologics Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
30.6.1. Biologics Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
30.6.2. Biologics Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
30.6.3. Biologics Market in Rest of Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

30.7. Data Triangulation and Validation

SECTION VII: STRATEGIC TOOLS

31. KEY WINNING STRATEGIES

32. PORTER FIVE FORCES ANALYSIS

33. VALUE CHAIN ANALYSIS

34. ROOTS STRATEGIC RECOMMENDATIONS

SECTION VIII: OTHER EXCLUSIVE INSIGHTS

35. INSIGHTS FROM PRIMARY RESEARCH

36. REPORT CONCLUSION

SECTION IX: APPENDIX

37. TABULATED DATA

38. LIST OF COMPANIES AND ORGANIZATIONS

39. CUSTOMIZATION OPPORTUNITIES

40. ROOTS SUBSCRIPTION SERVICES

41. AUTHOR DETAILS